CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

The European Patent Office declared a patent owned by CureVac valid, after a challenge from drugmaker BioNTech, the company said on Thursday. U.S.-listed shares of Germany-based CureVac rose 11.8% in ...

The European Patent Office’s latest report shows patent filings holding steady, with computer technology leading growth.

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

MUNICH, March 31, 2025 /PRNewswire/ -- The European Patent Office (EPO) published its annual Patent Index 2024 today, revealing that a total of 199,264 European patent applications were filed last ...

Companies and inventors from around the world filed 199,264 patent applications at the European Patent Office (EPO) last year ...

According to the latest Patent Index 2024, published today by the European Patent Office (EPO), Japan ranked third worldwide, following the United States and Germany. In 2024, Japanese companies and ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...

Germany-headquartered CureVac (Nasdaq: CVAC) late Thursday announced that the European Patent Office (EPO) has confirmed the ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company ...

European Patent Office received nearly 200 000 patent applications last year, with Japanese companies and inventors filing 10.6% of the total Electrical machinery/energy, transport and computers ...